Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
It has been suggested that the superiority of antidepressants over placebo in controlled trials is merely a consequence of side effects enhancing the expectation of improvement by making the patient realize that he/she is not on placebo. We explored this hypothesis in a patient-level post hoc-analysis including all industry-sponsored, Food and Drug Administration-registered placebo-controlled trials of citalopram or paroxetine in adult major depression that used the Hamilton Depression Rating Scale (HDRS) and included a week 6 symptom assessment (n=15). The primary analyses, which compared completers on active treatment without early adverse events to completers on placebo (with or without adverse events) with respect to reduction in the HDRS depressed mood item showed larger symptom reduction in patients given active treatment, the effect sizes being 0.48 for citalopram and 0.33 for paroxetine. In actively treated subjects reporting early adverse events, who also outperformed those given placebo, the severity of the adverse events did not predict response. Several sensitivity analyses, for example, including (i) those using change of the sum of all HDRS-17 items as effect parameter, (ii) those excluding all subjects with adverse events (that is, also those on placebo) and (iii) those based on the intention-to-treat population, were all in line with the primary analyses. The finding that both paroxetine and citalopram are clearly superior to placebo also when not producing adverse events, as well as the lack of association between adverse event severity and response, argue against the theory that antidepressants outperform placebo solely or largely because of their side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hamilton Depression Rating Scale: Has the Gold Standard Become a Lead Weight?
Bagby, R. M., Ryder, A. G., Schuller, D. R., & Marshall, M. B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.12.2163 · Cited by 1,148
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669
Active placebos versus antidepressants for depression
Moncrieff, J., Wessely, S., & Hardy, R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003012.pub2 · Cited by 342
How “blind” are double-blind studies?
Margraf, J., Ehlers, A., Roth, W. T., Clark, D. B., Sheikh, J., Agras, W. S., & Taylor, C. B. (1991) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.59.1.184 · Cited by 135
Hieronymus, F., Nilsson, S., & Eriksson, E. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.104 · Cited by 100
Self-citation
Research works printed but not linked: 26
- Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevent Treat 1998; 1, Article 2a. · DOI · Paper page
- Moncrieff J. Are antidepressants as effective as claimed? No, they are not effective at all. Can J Psychiatry 2007; 52: 96–97. · DOI
- Kirsch I. The emperor's new drugs: medication and placebo in the treatment of depression. Handb Exp Pharmacol 2014; 225: 291–303. · DOI
- Moncrieff J. Antidepressants: misnamed and misrepresented. World Psychiatry 2015; 14: 302–303. · DOI · Paper page
- Kirsch I. The Emperor's New Drugs: Exploding The Antidepressant Myth. Basic Books: New York, NY, 2010.
- Angell M. The Epidemic of Mental Illness: Why? New York Review of Books. June 23, 2011. Available at http://www.nybooks.com/articles/2011/06/23/epidemic-mental-illness-why/ . Accessed on 3 March 2017.
- Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994; 182: 547–551. · DOI · Paper page
- Barth M, Kriston L, Klostermann S, Barbui C, Cipriani A, Linde K. Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. Br J Psychiatry 2016; 208: 114–119. · DOI · Paper page
- Rabinowitz J, Werbeloff N, Mandel FS, Menard F, Marangell L, Kapur S. Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials. Br J Psychiatry 2016; 209: 427–428. · DOI · Paper page
- Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2016; 21: 523–530. · DOI · Paper page
- Nilsson ME, Koke SC. Defining treatment-emergent adverse events with the medical dictionary for regulatory activities (MedDRA). Drug Inf J 2001; 35: 1289–1299. · doi:10.1177/009286150103500425
- Letemendia FJ, Harris AD. The influence of side-effects on the reporting of symptoms. Psychopharmacologia 1959; 1: 39–47. · doi:10.1007/bf00408110
- Rabkin JG, Markowitz JS, Stewart J, McGrath P, Harrison W, Quitkin FM et al. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res 1986; 19: 75–86. · DOI
- Petkova E, Quitkin FM, McGrath PJ, Stewart JW, Klein DF. A method to quantify rater bias in antidepressant trials. Neuropsychopharmacology 2000; 22: 559–565. · DOI
- Liberman R. A criticism of drug therapy in psychiatry. Arch Gen Psychiatry 1961; 4: 131–136. · doi:10.1001/archpsyc.1961.01710080027005
- Klerman GL, Cole JO. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965; 17: 101–141. · DOI · Paper page
- Thomson R. Side effects and placebo amplification. Br J Psychiatry 1982; 140: 64–68. · DOI · Paper page
- Anderson IM. Antidepressant quandaries (letter). Br J Psychiatry 1998; 173: 181–182. · doi:10.1192/bjp.173.2.181b
- Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. Am J Psychiatry 2000; 157: 327–337. · DOI · Paper page
- Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 1958; 115: 459–464. · DOI · Paper page
- Lopez-Munoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009; 15: 1563–1586. · DOI · Paper page
- Scott AI, Perini AF, Shering PA, Whalley LJ. In-patient major depression: is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 1991; 40: 127–129. · DOI
- Vestergaard P, Gram LF, Kragh-Sorensen P, Bech P, Reisby N, Bolwig TG. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacol Ser 1993; 10: 190–198.
- Ansseau M, Darimont P, Lecoq A, De Nayer A, Evrad JL, Krémer P et al. Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology (Berl) 1994; 115: 254–260. · doi:10.1007/bf02244780
- Lapierre YD, Browne M, Oyewumi K, Sarantidis D. Alprazolam and amitriptyline in the treatment of moderate depression. Int Clin Psychopharmacol 1994; 9: 41–45. · DOI
- Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 2007; 29: 2319–2332. · DOI
Cited by
A neural circuit for comorbid depressive symptoms in chronic pain
Zhou, W., Jin, Y., Meng, Q., Zhu, X., Bai, T., Tian, Y., Mao, Y., Wang, L., Xie, W., Zhong, H., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0468-2 · Cited by 345
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Hieronymus, F., Lisinski, A., Nilsson, S., & Eriksson, E. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30216-0 · Cited by 73
Self-citationA mechanistic account of serotonin’s impact on mood
Michely, J., Eldar, E., Martin, I. M., & Dolan, R. J. (2020) · Nature Communications · doi:10.1038/s41467-020-16090-2 · Cited by 72
Hjorth, O. R., Frick, A., Gingnell, M., Hoppe, J. M., Faria, V., Hultberg, S., Alaie, I., Månsson, K. N. T., Rosén, J., Reis, M., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01682-3 · Cited by 46
Metadata
- Authors
- Hieronymus, F., Lisinski, A., Nilsson, S., & Eriksson, E.
- Venue
- Molecular Psychiatry
- Published
- 2017-07-25
- Volume
- 23
- Issue
- 8
- Pages
- 1731-1736
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2738633407
- Cited by
- 44
- References
- 5
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. https://app.cochat.ai/papers/10.1038/mp.2017.147
- The paper
- Hieronymus, F., Lisinski, A., Nilsson, S., & Eriksson, E. (2018). Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Molecular Psychiatry. https://doi.org/10.1038/mp.2017.147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.